

ings in Executive Officers" *** 11/2 19:00 TOPCON CORPORATION submitted "[Delayed]FY2020 Q2 Presentation Material" *** 11/2

Top

Search

Result

Company

Watchlist

Our message

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. [2395] [E05385]

Basic Info

Summary

Highlights

Financial Statements

Profit Analysis

Ranking

Fiscal year:

2019

☐ Q1☐ Q2☐ Q3☒ Y/E☒ US\$☐ Yen

Download(.xls)

Financial Statements (Consolidated)

FY03/2019

BS

P/L

CI

SS

CF

Consolidated P/L

(\$)

	Previous year (From Apr 1, 2017 To Mar 31, 2018)	Current year (From Apr 1, 2018 To Mar 31, 2019)
Net sales	156,255,177	141,081,881
Cost of sales	107,270,501	85,421,299
Gross profit	48,984,676	55,660,573
Selling, general and administrative expenses		
Remuneration for directors (and other officers)	2,594,512	2,470,340
Salaries and allowances	17,715,230	16,244,779
Retirement benefit expenses	169,512	199,432
Welfare expenses	2,981,617	2,690,251
Insurance expenses	279,123	268,574
Supplies expenses	778,944	773,745
Rent expenses	1,224,191	947,347
Depreciation	2,301,675	1,923,074
Traveling, transportation and vehicle expenses	1,754,537	1,855,257
Commission expenses	5,717,639	5,692,666
Bleeding animal maintenance expenses	5,340,173	4,808,893
Research and development expenses	4,879,471	3,061,699
Provision of allowance for doubtful accounts	129,179	37,274
Other	9,683,857	7,210,884
Total selling, general and administrative expenses	55,549,736	48,184,269
Operating profit (loss)	-6,565,051	7,476,304
Non-operating income		
Interest income	85,345	166,772
Foreign exchange gains	-	6,795,234
Share of profit of entities accounted for using equity method	6,004,217	3,257,825
Other	1,934,017	2,394,495
Total non-operating income	8,023,588	12,614,335

Non-operating expenses		
Interest expenses	3,520,369	3,403,874
Foreign exchange losses	4,023,701	-
Commission expenses	1,328,633	1,413,298
Provision of allowance for doubtful accounts	-	631,543
Other	239,072	103,180
Total non-operating expenses	9,111,785	5,551,915
Ordinary profit (loss)	-7,653,247	14,538,724
Extraordinary income		
Gain on sales of non-current assets	16,858	43,139
Gain on change in equity	1,283,763	-
Gain on sales of investment securities	1,723	-
Gain on sales of shares of subsidiaries and associates	3,207,991	6,716,398
Other	12,321	-
Total extraordinary income	4,522,694	6,759,546
Extraordinary losses		
Loss on sales of non-current assets	2,231	-
Loss on retirement of non-current assets	547,769	1,535,147
Impairment loss	2,051,167	2,621,065
Settlement package	1,639,778	-
Loss on valuation of investment securities	-	177,115
Loss on sales of shares of subsidiaries and associates	6,562,604	2,092,405
Other	260,081	-
Total extraordinary losses	11,063,658	6,425,750
Profit (loss) before income taxes	-14,194,211	14,872,520
Income taxes - current	914,307	459,204
Income taxes - deferred	18,035,552	-3,235,021
Total income taxes	18,949,859	-2,775,818
Profit (loss)	-33,144,079	17,648,338
Profit attributable to non-controlling interests	326,817	76,421
Profit (loss) attributable to owners of parent	-33,470,896	17,571,916

This financial information has been prepared by Internet Disclosure Co., Ltd. based on XBRL data delivered by TDnet. Conversion is done using year-end closing rates. These contents have been produced with the utmost care. However, we bear no responsibility for content errors.

All intellectual property rights relating to information in our database belong to Internet Disclosure, and the providers of the information. Some of our information is provided by the Tokyo Stock Exchange. Copyright © 2011. Internet Disclosure Co., Ltd. All Rights Reserved.

This site is operated by [Internet Disclosure Co., Ltd.](#)